Novartis Settlement Marks a Turning Point in Biomedical Ethics In a landmark decision finalized this month, Novartis has settled a lawsuit brought by the estate of Henrietta Lacks. The suit alleged the pharmaceutical giant unjustly profited from HeLa cells – cells taken from Lacks’ tumor without her knowledge in 1951. While the details of the … Read more
Denmark’s Economic Puzzle: Why Consumer Gloom Persists Despite Strong Numbers Denmark presents a fascinating economic paradox. Despite record-high house prices and near-zero unemployment, consumer sentiment remains surprisingly subdued. According to Helge Pedersen, chief economist at Nordea Bank, ordinary Danes are still deeply concerned about inflation, even as the official rate has fallen to 0.8%. The … Read more
Minnesota’s 340B Drug Pricing Program: A Glimpse into the Future of Drug Discounts A recent report from the Minnesota Department of Health reveals that hospitals and clinics participating in the 340B Drug Pricing Program generated at least $1.34 billion in revenue in 2024. The program, a federal initiative allowing eligible healthcare providers to purchase discounted … Read more
Inovio Pharmaceuticals Investors Face Deadline in Securities Fraud Lawsuit Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to join a class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set, according to Rosen Law Firm, a global investor rights … Read more
DOJ Backs AbbVie in 340B Drug Pricing Dispute: What’s at Stake? The U.S. Department of Justice (DOJ) is siding with pharmaceutical giant AbbVie in a lawsuit against the state of Colorado, escalating a critical battle over the 340B Drug Pricing Program. This marks the first time the federal government has weighed in on the numerous … Read more
FDA Rejection of Rare Disease Therapy Sparks Debate Over Agency Direction A promising cell therapy developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals for a rare blood cancer faced a sudden reversal in its path to FDA approval. Internal reviewers had previously recommended clearance, yet the agency rejected the drug last month, citing insufficient clinical … Read more
GSK’s $950 Million Bet on 35Pharma: A New Wave in Pulmonary Hypertension Treatment? GSK has acquired privately held 35Pharma for $950 million, a move signaling increased industry focus on pulmonary arterial hypertension (PAH). The acquisition centers around HS235, an experimental drug poised to enter clinical trials for PAH, a condition characterized by high blood pressure … Read more
Medicare Drug Price Battles: What Trump’s Plans Mean for Your Wallet The pharmaceutical industry is bracing for potential showdowns with the Trump administration over proposals designed to lower Medicare drug costs. These plans, centered around aligning U.S. Prices with those paid in other developed nations, could dramatically reshape the landscape of prescription drug affordability. But … Read more
Novo Nordisk’s Price Cuts: A Turning Point for GLP-1 Medications? Novo Nordisk’s announcement of significant price reductions for its blockbuster GLP-1 medications – Ozempic, Rybelsus and Wegovy – has sent ripples through the healthcare industry. The move, slated to take effect January 1, 2027, will lower the list price of each drug to $675 per … Read more
Bayer Challenges J&J’s Erleada Marketing Claims in Court German pharmaceutical company Bayer has launched a lawsuit against Johnson & Johnson (J&J) and its subsidiary Janssen Biotech, alleging false advertising related to their prostate cancer drugs, Erleada and Nubeqa. The legal action, filed in the United States District Court for the Southern District of New York, … Read more